NCT05037799View on ClinicalTrials.gov

Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease

Active, not recruitingOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Ischemic Heart Disease
Interventions
DRUG

Rb-82 Radioisotope

Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight

Trial Locations (1)

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
collaborator

Jubilant DraxImage Inc.

INDUSTRY

lead

Ottawa Heart Institute Research Corporation

OTHER